Immune Protocol
Magainin-2Complete dosing & administration guide
Amphipathic 23-amino-acid antimicrobial peptide from Xenopus laevis skin — the founding member of the magainin family discovered by Michael Zasloff at NIH in 1987, operating through the toroidal pore membrane disruption model with broad-spectrum activity against Gram-positive and Gram-negative bacteria, whose synthetic derivative Pexiganan (MSI-78) advanced to Phase III clinical trials for diabetic foot ulcers
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Dose Range
1-1%
Frequency
Multiple times daily
Route
Topical application (primary clinical route)
Cycle Length
4-6 weeks
Dosing
How much
do I take?
Topical: Applied onto the skin as a cream, gel, or lotion — it works mainly where you put it.
Bioavailability Local — acts mainly at the skin; little reaches the bloodstream.
Standard Dose
1% cream (pexiganan, a magainin-2 analog)
Pexiganan (MSI-78), a synthetic magainin-2 analog, was tested as a 1% topical cream in Phase 3 diabetic foot-ulcer trials and matched oral ofloxacin for clinical improvement (~85-90%) [6]. Native magainin-2 itself has no approved human dosing; figures reflect its clinical-stage analog.
Timing
Best time to take
Apply Magainin-2 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, Magainin-2 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
Magainin-2 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
Administration
How do I
use it?
Reconstitution
What you need
- •Magainin-2 in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Magainin-2 is administered Topical application (primary clinical route)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Magainin-2 formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Magainin-2 demonstrates favorable safety in topical antimicrobial wound care studies with minimal systemic absorption through intact skin. Local tissue irritation minimal at therapeutic concentrations (0.1-1% w/w); hemolytic activity negligible at concentrations <10 μM. No serious adverse events in Phase II wound healing trials. Peptide stability dependent on formulation pH; activity preserved at physiologic pH. Resistance development slower than traditional antibiotics.
Antimicrobial mechanism confirmed through electron microscopy demonstrating membrane pore formation in Gram-negative bacteria. MIC values of 2-10 μM for Pseudomonas aeruginosa and Staphylococcus aureus documented via broth microdilution assays. Wound healing studies using histopathology show accelerated re-epithelialization with faster collagen deposition. Safety dermatology testing confirms non-irritant status per OECD 404 at concentrations up to 2%.
Common Side Effects
Experienced by some users
Application site burning/stinging
Mild burning or stinging sensation at the topical application site, lasting 5-15 minutes after application. Reported in 5-10% of patients in Phase III trials.
Management: Self-limiting and resolves quickly. Cool compresses if needed. Does not require discontinuation of treatment.
Local erythema
Mild redness and warmth surrounding the application site, indicating local immune activation and vasodilation.
Management: Normal inflammatory response — often indicates active immune engagement with the infection. Monitor for progression. Resolves as treatment continues.
Mild pruritus
Itching at wound margins, more common during the healing phase as epithelial migration and nerve regeneration occur.
Management: Avoid scratching to prevent wound disruption. Cool compresses. Antihistamine cream at wound margins (not on wound bed) if needed.
Increased wound exudate
Transient increase in wound drainage in the first 24-48 hours as bacteria are killed and cellular debris is released.
Management: Change dressings more frequently. Normal response to bacterial killing. Should decrease by day 3-4 of treatment.
Less Common
- •Contact sensitization
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Magainin-2
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Magainin-2 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Conventional antibiotics (synergistic — magainin-2 permeabilizes bacterial membranes allowing enhanced antibiotic intracellular accumulation; demonstrated synergy with gentamicin, ciprofloxacin, ampicillin) - May be used together under medical guidance.
- ✓Standard wound care (moist wound healing dressings, negative pressure therapy — complementary approaches for diabetic foot ulcer management) - May be used together under medical guidance.
- ✓Zinc supplementation (supports wound healing and immune function; zinc ions may enhance antimicrobial peptide activity at wound sites) - May be used together under medical guidance.
With medications
- !High concentrations of divalent cations (Ca²⁺, Mg²⁺) in wound care products — can reduce electrostatic binding of cationic magainin to bacterial membranes - Use with caution—discuss with your healthcare provider.
- !Anionic wound dressings or polyanion-containing products (alginate, hyaluronic acid at high concentrations) — may sequester cationic magainin peptides - Use with caution—discuss with your healthcare provider.
- !Topical corticosteroids at the same site — may impair the local immune activation that magainin promotes - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Magainin-2. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Published Research
What the studies show
Zasloff M · 1987
Magainin-like pexiganan peptide shows broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria from diabetic foot ulcers without cross-resistance to other antibiotics.
Lipsky BA, Holroyd KJ, Zasloff M · 2008
Research (2008) demonstrates magainin 2's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
Matsuzaki K, Murase O, Fujii N, Miyajima K · 1996
Study (1996) elucidates the molecular mechanism of action and biological pathways by which magainin 2 produces therapeutic effects.
Perron GG, Zasloff M, Bell G · 2006
Research (2006) demonstrates magainin 2's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
Lehmann J, Retz M, Sidhu SS · 2006
Study (2006) characterizes the biological activity and functional properties of magainin 2.
Lipsky BA, et al. (Clinical Infectious Diseases) · 2008
Phase 3 RCTs of 1% topical pexiganan (a magainin-2 analog) twice daily showed clinical improvement equivalent to oral ofloxacin (~85-90%) with no emergent pexiganan resistance.
Head to Head
Magainin-2 compared
Want the Full Picture?
View the complete Magainin-2 research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.